Organic Active Ingredients TRIZ Cases

Quinoline derivative plus epirubicin targets refractory sarcoma with limited cardiotoxicity.

This case combines budesonide 21-phosphate salts with formoterol to support stable aqueous delivery and reduce airway dysfunction.

This case uses meglumine salt crystallization to improve sulfasalazine bioavailability while limiting hygroscopicity and dose burden.

Explore pyridonopyrimidine derivatives designed to inhibit multiple RSK isoforms and support targeted cancer drug development.

Multiparticulate rosuvastatin pellets ease swallowing while preserving rapid release and stability.

This case uses topical abemaciclib to inhibit IκBζ, reducing keratinocyte hyperproliferation and limiting systemic side effects.

This case combines rifaximin with vancomycin or metronidazole to target gut bacteria, reduce neurotoxins, and ease ASD symptoms.

Below critical gelling concentration, hypotonic polymers spread across mucosa before forming a retained gel barrier.

This case shows how Compound 1 tablets reduce HTT mRNA and protein levels while supporting disease modification in Huntington’s disease.

This case uses PC, PE, and PS to mature tumor-associated dendritic cells, increase cytokines, and suppress tumor growth.

Crystallization produces stable, high-purity BET inhibitor Form VII without chromatography.

This composition inhibits hyaluronidase and promotes hyaluronic acid synthesis, extending filler effects while limiting skin irritation.

Ionizable lipid nanoparticles use pH-responsive charge and multifunctional lipids to protect large saRNA constructs and aid cell uptake.

This case combines spermidine with nicotinamide to preserve cardiovascular benefits while reducing glucose and insulin disturbances.

ECM, chemokine inhibitors, migration factors, and protease pretreatment replace stem cell transplantation for dental tissue regeneration.

This case identifies n-3 DPA-derived resolvins and maresins that reduce neutrophil chemotaxis and enhance macrophage phagocytosis.

This case uses tailored substituents on a pyrimidine scaffold to balance kinase efficacy and selectivity in cancer treatment.

Engineered variable-region sequences and phage screening block PD-L1/PD-1 signaling to enhance T-cell function.

This case uses hydrophilic linker segments to support higher drug loads while preserving conjugate stability and antibody affinity.

Targeted compounds inhibit MOZ, HBO1, TIP60, and MOF to support cancer treatment and tumor-cell sensitization.

Heterocyclic compounds inhibit Polθ-mediated MMEJ, sensitizing repair-deficient cancer cells to combined treatment.

This case uses renal-function-based dosing and monitoring to balance alopecia areata hair regrowth with patient safety.

Formula (I) compounds inhibit LDHA/LDHB with improved selectivity, solubility, permeability, and bioavailability.

Guide-region optimization and rAAV delivery enable alpha-synuclein knockdown with neuroprotection while helping limit neuronal toxicity.

Enzymatic sulfur oxidation streamlines morpholine pyrimidine synthesis for commercial production.

Controlled crystallization of Forms 1 and 2 balances linaprazan glurate solubility, hygroscopicity, and chemical stability.

This case examines once-daily AZD9833 dosing to improve ERα down-regulation and oral treatment efficacy in breast cancer.

Benzothiazepine derivatives target ASBT and LBAT while balancing potency and bioavailability.

Chitosan and genipin crosslink during catheter delivery to form a cohesive scaffold that fills aneurysms and may reduce recanalization.

This case applies orthosteric and allosteric S1P1 agonists to target receptor subtypes and support reversible lymphopenia.

This case develops tunable small molecules to inhibit NSD1, NSD2, and NSD3 methyltransferases for cancer treatment.

Specific intermediates, protecting groups, and reaction conditions support robust, higher-yield GLP-1 RA manufacturing at scale.

Deuterated fused gamma-carbolines combine 5-HT2A antagonism with partial μ-opioid agonism to improve OCD response and pharmacokinetics.

This case varies conjugate valency, chain length, and hydrophobicity to direct siRNA across kidney and extrahepatic tissues.

Organometallic, titanium, zirconium, and catalytic steps provide an efficient route to Cot inhibitors without azide-related explosiveness.

This case uses N-acetyl-galactosamine-linked RNAi agents to deliver APOC3 silencing to hepatocytes and reduce lipid levels.

This case uses optimized Tegaserod treatment to inhibit JAK-STAT3, suppress tumor growth, and activate immune responses.

This case isolates Ambrosia sesquiterpene lactones to block cancer proliferation and promote apoptosis through covalent protein targeting.

Explore reversible BTK inhibitor compounds that bypass C481 mutations while limiting EGFR inhibition and gastrointestinal side effects.

A topical zinc, arginine gluconate, and ascorbic acid blend targets alopecia locally.

This case combines MANP and furosemide to lower blood pressure and counter diuretic-related aldosterone elevation in resistant hypertension.

This case shows how cyclobutyl dihydroquinoline sulfonamides improve Nav1.7 selectivity for pain relief while reducing cardiac risk.

This case uses CRF1 receptor blockade to lower CAH steroid biomarkers and reduce reliance on high-dose corticosteroids.

This case uses pre- and post-treatment TCTP Ser46 phosphorylation to identify AML patients likely to respond to onvansertib.

Wearable illumination and topical compositions support convenient psoriasis treatment.

A single lentiviral vector combines HPRT knockdown and gamma-globin expression to support selection and engraftment.

This case pairs FUS-targeting PROTACs with transferrin receptor aptamers for brain delivery and degradation of mutant FUS.

XRPD-defined amorphous and crystalline forms address BTK inhibitor stability and solubility for therapeutic use.

This case uses circular topology to support rolling circle translation, reduce immunogenicity, and extend cellular persistence.

Formula-based compounds inhibit Bunyaviridae replication across major viral threats.

Seabuckthorn alkaloid protects myocardium against doxorubicin-induced toxicity by suppressing p-JNK and Cleaved-Caspase-3, preventing congestive heart failure.

Genistein-7-O-phosphate increases bone density and strength while avoiding tumor risks associated with estrogen replacement therapy.

Amorphous lurasidone solid dispersion overcomes pH-dependent precipitation to maintain bioavailability without dietary restrictions.

Hydrothermal processing with chitosan templates synthesizes VS2 nanoflowers, replacing expensive organic solvents and harsh conditions.

Specific alpha1a-adrenergic receptor agonists enhance cardiac output and cerebral blood flow by resolving insufficient subtype selectivity.

Modifying the dihydropyrimidine core structure eliminates hERG cardiotoxicity while enhancing liver exposure and antiviral efficacy against hepatitis B.

An adhesive plaster containing enantiomerically pure S-citalopram reduces skin irritation while maintaining percutaneous absorption.

Self-emulsifying drug delivery system in transdermal patches improves treprostinil bioavailability while reducing injection pain and lung irritation.

Alternating magnetic fields activate embedded magnetic nanoparticles to produce localized heat, targeting residual tumor cells while sparing healthy tissue.

Administering miR-101-3p inhibitors reverses oxidant stress-induced Tet1 downregulation, enhancing NKT cell immunosurveillance against colorectal cancer.

Detecting specific microRNAs like miR-130b-3p addresses unaddressed molecular mechanisms in polycystic ovary syndrome diagnosis.

A vaporizable cannabinoid composition uses a carrier liquid solution to deliver bio-active ingredients via mucosal absorption.

Universal sequencing detects novel ESR1 mutations to overcome treatment resistance development during hormone therapy.

Cleavable linkers in polypeptide conjugates enable targeted intracellular release, reducing systemic toxicity and improving half-life.

A targeted peptide-modified nanodrug delivery system enhances drug solubility and stability through amphiphilic block copolymer micelles.

Substituted quinoline compounds selectively modulate RORγt to reduce IL-17 production, addressing off-target effects of broad immunosuppressants.

Phyllochlorin analogues resolve the trade-off between singlet oxygen yield and dark toxicity in tumor treatment.

C-glycoside linkages prevent acidic hydrolysis while alkyl substituents improve oral bioavailability for inflammation treatment.

Debossed tablet cores receive heterogeneous coatings to accelerate water penetration and disintegration.

Agelastatin alkaloids arrest the G2/M phase to resolve ineffective proliferation inhibition while minimizing hemolytic activity.

A modulator of the retinoid metabolic pathway increases memory T cell concentration in a T cell population.

Micronized organic and inorganic UV filters in an artificial tear base prevent eye irritation and vision blurring while blocking UVA and UVB rays.

Novel heterocyclic CXCR3 antagonists inhibit inflammatory pathways, addressing the lack of effective treatments for chronic diseases.

Oral administration of CGRP receptor antagonists bypasses blood-brain barrier constraints to restore weight recovery.

Combining BTK and ROR-1 antagonists inhibits Wnt5a-induced activation in chronic lymphocytic leukemia cells.

Programmable base editors substitute pathogenic amino acids via targeted deamination, minimizing random indels and translocations to treat sickle cell disease.

Imidazopyridine compounds degrade estrogen receptor alpha via chaperone targeting, bypassing ligand binding domain mutations.

Quinoxaline kinase inhibitors address the lack of specific therapeutic agents by targeting tyrosine and serine/threonine kinases to treat cancer.

GalNAc-conjugated saRNA up-regulates CEBPA expression in hepatocytes by binding asialoglycoprotein receptors, eliminating transfection agent toxicity.

A piperazine compound combined with a PD-1 inhibitor antibody addresses limited monotherapy efficacy by delivering significant synergistic antitumor effects.

Complementary oligonucleotides reverse aptamer activity, eliminating bleeding risks from irreversible inhibitors.

A prodrug composition uses a disulfide spacer and beta-1,3-D-glucan carrier to transport active drugs across the intestinal mucosa.

Segmenting AK6 and GPX5 protein detection resolves the trade-off between diagnostic precision and method complexity in male infertility assessment.

Dendropanax morbifera extract addresses insomnia side effects by activating GABA receptors without residual sedation.

Co-crystallizing Pomalidomide with Gentisic acid overcomes low water solubility to improve oral bioavailability and treatment efficacy.

Crystalline Form II of nicotinamide riboside chloride improves chemical purity and shelf-life by transforming amorphous material into a stable solid phase.

Metal salts and polyhydric alcohols boost delivery efficiency while reducing leakage risk through viscosity control.

Replacing costly protein factors, this bisphosphonate compound enhances bone affinity and osteogenesis while avoiding antigenicity and inflammation.

Fecal microbiota analysis identifies specific bacterial taxa to predict rifaximin response, reducing antibiotic resistance risks.

A multimicrocapsular oral pharmaceutical uses a composite coating to control active principle release kinetics through dual triggering mechanisms.

Formula I cyclopropylamines resolve the trade-off between inhibitor activity and pharmacokinetic properties for effective cancer treatment.

Neurosomes functionalized with neural proteins deliver therapeutic agents to specific cells, resolving safety issues from cellular transplantation.

Segmented lipid nanoparticles with surface ligands enable precise localized delivery of nucleic acid therapeutics.

Systematic solvent and pH adjustments yield stable polymorphs, resolving the trade-off between manufacturing complexity and drug bioavailability.

Replacing sodium cyanate with 4-nitrophenyl chloroformate prevents biuret impurity formation, eliminating the need for extensive purification steps.

A coagulation calculator uses logit 1/INR to compute optimal warfarin dosages.

Enteric coatings dissolve in the duodenum to reduce gastrointestinal side effects while maintaining therapeutic efficacy.

Enterobactin-cargo conjugates transport antibiotics into bacterial cells via siderophore uptake machinery.